Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or monoclonal antibodies that typically target a single protein, multispecific compounds are engineered to harness multiple mechanisms of action within a single molecule. They orchestrate biology rather than just blocking it. Read More
Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital. Read More
IKZF1-4 are transcription factors that regulate cellular differentiation, proliferation and survival. At the American Chemical Society (ACS) Spring 2026 meeting this week in Atlanta, Bristol Myers Squibb Co. detailed the identification and preclinical profile of BMS-986482, a next-generation investigational cereblon E3 ligase modulator (CELMoD) degrader designed to target IKZF1-4 factors. Read More
Researchers from the Indian Institute of Technology Bombay have reported the preclinical development of a new synthetic antimicrobial class incorporating organic metallophores, which yielded two optimized leads – VY-AD-4-11-6 and VY-AD-4-22-6 – from a 30-compound SAR series. Read More
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized new polycyclic heteroaryl compound acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of diabetes and obesity, among others. Read More
Onkure Therapeutics Inc. has announced an oversubscribed $150 million private placement which the company intends to use to fund the preclinical and clinical development of its next-generation PI3Kα pan-mutant selective inhibitor candidates in breast cancer and vascular anomalies. Read More
Helmholtz Zentrum München Universität Hannover has disclosed new heterocyclic compounds designed for use in the treatment of cancer and viral infection. Read More
Aconcagua Bio Inc. has divulged new calcitonin (CALCR; CT-R) and amylin receptor agonists intended for use in the treatment of pain, neurodegeneration, bone, metabolic and cardiovascular disorders. Read More
Previously, Chinese researchers used long-read RNA sequencing to identify a unique alternative splicing variant of CD44 transmembrane protein, named CD44E, which is highly expressed in hepatocellular carcinoma (HCC) tumors compared to adjacent nontumoral liver tissues. In a new study, the team analyzed the Genotype-Tissue Expression (GTEx) database and confirmed that CD44E expression is limited in essential normal organs, while CD44S standard isoform is broadly expressed on most cell types. Read More
Sichuan University has identified new G-protein coupled receptor 65 (GPR65) antagonists potentially useful for the treatment of cancer and epilepsy. Read More
Chengdu Sibeibo Pharmaceutical Technology Co. Ltd. has reported new poly(ADP-ribose) polymerase 14 (PARP-14; ARTD8) inhibitors potentially useful for the treatment of cancer, asthma, atopic dermatitis and infectious pneumonia. Read More
In recent work, researchers from Shanghai Jiaotong University School of Medicine and Shanghai Colorectal Cancer Research Center reported that the transcription factor hematopoietically expressed homeobox (HHEX) promotes tumorigenesis in colitis-associated colorectal cancer. In a new paper, the team aimed to further characterize the biological function and potentially dysregulated mechanisms of HHEX during intestinal inflammation, which remained largely unexplored. Read More
